Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company formed to pursue a business combination in the pharmaceutical and domestic drug-manufacturing sector. The SPAC's name and stated focus reflect the broader policy and industry push to reshore pharmaceutical production to the United States, targeting potential targets across drug development, contract manufacturing, and related life sciences verticals. The company filed an 8-K current report with the SEC on May 1, 2026, under accession number 0001213900-26-051018. For complete data on DMAAR's sponsor, timeline, deal status, and comparable transactions, sign up for full access at SpacDesk.